Description_x000D_ Application_x000D_ Zoledronic acid monohydrate has been used:_x000D_ • as an inhibitor for cell proliferation in glioblastoma, breast cancer tumor and prostate cancer cell line LAPC4_x000D_ • as a conjugate with D,L-lactide 75: glycolide 25 (PLGA) to analyze its bone formation functionality in distal femur_x000D_ • as an inhibitor for farnesyl diphosphate synthase enzyme in glioblastoma cells_x000D_ Packaging_x000D_ 10, 50 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget′s disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones._x000D_ Features and Benefits_x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more._x000D_ Legal Information_x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC